Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

# Johnson & Johnson

All time
EU watchdog reviewing Janssen vaccine data after US regulator warns of rare neurological reaction
Data shows Johnson and Johnson's Covid-19 vaccine is effective against Delta variant
US tells J&J millions of vaccine doses can't be used due to possible contamination
Just 59 Covid-19 patients in hospital, the lowest figure in nine months
US Supreme Court rejects Johnson & Johnson’s appeal against $2 billion talc verdict
Update on use of J&J and AstraZeneca vaccines for under-50s expected in coming days
Pregnant women to be offered Covid-19 vaccines as Cabinet accepts NIAC advice
US health officials lift suspension of Johnson & Johnson Covid jab
Johnson & Johnson to deliver vaccine to Europe from 19 April
The single-dose Johnson & Johnson Covid-19 vaccine has been approved by the European Medicines Agency
J&J vaccine to be approved today - but will supply issues hamper Ireland's progress?
The Johnson & Johnson Covid-19 vaccine could get approved in Europe next month - here's everything you need to know
Johnson & Johnson subsidiary applies to EMA for Covid-19 vaccine approval
Johnson & Johnson global trial finds single-dose Covid-19 vaccine is 66% effective
Johnson and Johnson to stop selling talc baby powder in US and Canada — but not in Ireland
Explainer: Why a US court ruling could be a turning point in one of the country's worst-ever drug epidemics
Johnson & Johnson ordered to pay over $570 million in landmark opioid trial
Johnson & Johnson ordered to pay woman €350m in cancer lawsuit
J & J to pay out $2.2 billion over false marketing and kickbacks to doctors
Companies cease development of Alzheimer's drug after failure in late-stage trials
133 jobs to go at Johnson & Johnson in Cashel